SecBot SecBot

IRLA

IRulya Therapeutics Inc.
Nasdaq· CIK 0001662774 Biotech & Drug Discovery
$31.11 −1.97 (−5.96%)
Oct 26 4:00 PM ET · prev $33.08
Market cap
$355.9M
Small cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$71.00
+128% · range $65.00–98.00
Next earnings
Nov 10
in 15 days · EPS est. −$1.20
1 year
−91.3%
from $358.00 · Oct 27
30 days
+7.3%
from $29.00
52-week range
$16.00–880.00
−96% from high · low Mar 20
Avg volume 20D
72.0K
Oct 20 spike 317.1K
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 0 bearish · 0 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 7/10 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL Quince Therapeutics stockholders approved the 2026 Equity Incentive Plan (initial reserve of 821,872 shares…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • A Jun 23 Cantor Fitzgerald initiates
  • A Jun 24 Leerink Partners initiates
  • A Jul 29 Oppenheimer initiates
  • A Sep 22 Citizens upgrades
  • A Sep 24 Rodman & Renshaw initiates
  • A Oct 9 Raymond James initiates

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (1 new), 0 trimmed or exited. Largest new: Balyasny Asset Management $12.6M.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$8.800 → −$1.200 over 90 days.

  • TrendRANGE

    0% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.6M
in new stakes
FundMoveSharesValue
BALYASNY ASSET MANAGEMENT L.P.NEW69,967$12.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +128%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 9, 2026Raymond James
INITIATE
INITIATEOutperform
Sep 24, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
Sep 22, 2026Citizens
UPGRADE
UPGRADEMarket Outperform
Aug 18, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jul 29, 2026Oppenheimer
INITIATE
INITIATEOutperform
Jun 24, 2026Leerink Partners
INITIATE
INITIATEOutperform

Earnings setup

Estimates
Nov 10
reports in 15 days
−$1.20
EPS estimate, this quarter
+86%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.20-$1.40–-$0.83-9.1%$0.00
Next Q-$1.11-$1.60–-$0.71-28.3%$0.00
Current FY-$3.65-$8.00–-$0.96+0.0%$0.00
Next FY-$4.68-$6.60–-$3.49+0.0%$0.00
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Dirk Thye, an officer of IRulya Therapeutics Inc., filed a Form 144 on October 21, 2026, indicating intent to sell…
144 — Impact 3/10
Oct 20, 2026 Listing status
Listing Status: IRLA — Normal (was Deficient)
IRulya Therapeutics Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Oct 19, 2026 SEC
Catherine M. Bonuccelli filed a Form 3 initial statement of beneficial ownership with IRulya Therapeutics Inc…
3 — Impact 2/10
Oct 19, 2026 SEC
James Elwood Valentine filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting his status…
3 — Impact 2/10
Jun 30, 2026 Inst.
BALYASNY ASSET MANAGEMENT L.P. — NEW
69,967 shares ($12.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
IRLA Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 20, 2026
Listing
Listing Status: IRLA — Normal (was Deficient)
IRulya Therapeutics Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Oct 15, 2026
Press release
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on…
Oct 12, 2026
Listing
New Listing: IRLA — IRulya Therapeutics Inc. - Common Stock
Listed on exchange Q

SecBot reports

10 filings · 0 bullish · 0 bearish · 10 neutral
All IRLA filing & press-release reports (10)